Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Cidara Therapeutics (CDTX) over the last 6 years, with Dec 2024 value amounting to $6.3 million.

  • Cidara Therapeutics' Shares Outstanding (Diluted Average) rose 311.67% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 311.67%. This contributed to the annual value of $6.3 million for FY2024, which is 45.25% up from last year.
  • Cidara Therapeutics' Shares Outstanding (Diluted Average) amounted to $6.3 million in FY2024, which was up 45.25% from $4.4 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Shares Outstanding (Diluted Average) peaked at $69.9 million during FY2022, and registered a low of $4.4 million during FY2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $6.3 million (2024), whereas its average is $26.9 million.
  • Per our database at Business Quant, Cidara Therapeutics' Shares Outstanding (Diluted Average) plummeted by 93.74% in 2023 and then skyrocketed by 45.25% in 2024.
  • Cidara Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $41.6 million in 2020, then rose by 26.22% to $52.5 million in 2021, then soared by 33.18% to $69.9 million in 2022, then tumbled by 93.74% to $4.4 million in 2023, then soared by 45.25% to $6.3 million in 2024.